Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
P/B ratio for Olema Pharmaceuticals, Inc. (OLMA)
P/B ratio as of 2023: 2.50
According to Olema Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.50. At the end of 2022 the company had a P/B ratio of 0.50.
P/B ratio history for Olema Pharmaceuticals, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.50 |
| 2022 | 0.50 |
| 2021 | 1.30 |
| 2020 | 5.59 |
| 2019 | -185.80 |
| 2018 | -110.04 |